TY - JOUR
T1 - Matrix metalloproteinase 9 gene polymorphisms are associated with a multiple family history of gastric cancer
AU - The Japan Multi-institutional Collaborative Cohort Study Group
AU - Okada, Rieko
AU - Naito, Mariko
AU - Hattori, Yuta
AU - Seiki, Toshio
AU - Wakai, Kenji
AU - Nanri, Hinako
AU - Watanabe, Miki
AU - Suzuki, Sadao
AU - Kairupan, Tara Sefanya
AU - Takashima, Naoyuki
AU - Mikami, Haruo
AU - Ohnaka, Keizo
AU - Watanabe, Yoshiyuki
AU - Katsuura-Kamano, Sakurako
AU - Kubo, Michiaki
AU - Hamajima, Nobuyuki
AU - Tanaka, Hideo
N1 - Publisher Copyright:
© 2016, The International Gastric Cancer Association and The Japanese Gastric Cancer Association.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Background: A family history of gastric cancer (GC) is a well-known risk factor of GC. Genetic variations in genes of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) have been related to the risk of GC, but their association with familial background is not clear. We investigated whether individuals with a multiple family history of GC have more risk genotypes of MMP/TIMP genes. Methods: We genotyped ten common functional polymorphisms of MMP/TIMP genes in 4427 individuals aged 35–69 years without a history of GC who were enrolled in the Japan Multi-institutional Collaborative Cohort Study. Individuals who have two or more first-degree relatives (parents and siblings) with GC were categorized as having a multiple family history. Odds ratios (ORs) for multiple family history compared with no family history were calculated. Results: MMP9 279QQ (rs17576) was more frequently observed in individuals whose both parents had a history of GC (n = 23) and in individuals for whom one parent and their sibling(s) had a history of GC (n = 36) compared with those with no family history (n = 3816) [30.4 % vs 11.6 %, OR 4.34, 95 % confidence interval (CI) 1.45–13.03 and 16.7 % vs 11.6 %, OR 2.26, 95 % CI 0.81–6.27 after adjustment for age, sex, and current smoking]. The population attributable fraction was 38.1 %. The haplotype MMP9-1562C/279Q/668Q was more frequently observed in individuals whose both parents had a history of GC and in individuals for whom one parent and their sibling(s) had a history of GC compared with those with no family history (OR 3.35, 95 % CI 0.75–14.96 and OR 3.51, 95 % CI 1.35–9.15 respectively). Conclusions: MMP9 polymorphisms were associated with a multiple family history of GC. Screening for these genotypes together with familial background may help us to identify individuals at an increased risk of GC.
AB - Background: A family history of gastric cancer (GC) is a well-known risk factor of GC. Genetic variations in genes of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) have been related to the risk of GC, but their association with familial background is not clear. We investigated whether individuals with a multiple family history of GC have more risk genotypes of MMP/TIMP genes. Methods: We genotyped ten common functional polymorphisms of MMP/TIMP genes in 4427 individuals aged 35–69 years without a history of GC who were enrolled in the Japan Multi-institutional Collaborative Cohort Study. Individuals who have two or more first-degree relatives (parents and siblings) with GC were categorized as having a multiple family history. Odds ratios (ORs) for multiple family history compared with no family history were calculated. Results: MMP9 279QQ (rs17576) was more frequently observed in individuals whose both parents had a history of GC (n = 23) and in individuals for whom one parent and their sibling(s) had a history of GC (n = 36) compared with those with no family history (n = 3816) [30.4 % vs 11.6 %, OR 4.34, 95 % confidence interval (CI) 1.45–13.03 and 16.7 % vs 11.6 %, OR 2.26, 95 % CI 0.81–6.27 after adjustment for age, sex, and current smoking]. The population attributable fraction was 38.1 %. The haplotype MMP9-1562C/279Q/668Q was more frequently observed in individuals whose both parents had a history of GC and in individuals for whom one parent and their sibling(s) had a history of GC compared with those with no family history (OR 3.35, 95 % CI 0.75–14.96 and OR 3.51, 95 % CI 1.35–9.15 respectively). Conclusions: MMP9 polymorphisms were associated with a multiple family history of GC. Screening for these genotypes together with familial background may help us to identify individuals at an increased risk of GC.
KW - Epidemiology
KW - Family history
KW - Gastric cancer
KW - Genetic polymorphism
KW - MMP9
UR - http://www.scopus.com/inward/record.url?scp=84962684984&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84962684984&partnerID=8YFLogxK
U2 - 10.1007/s10120-016-0608-2
DO - 10.1007/s10120-016-0608-2
M3 - Article
C2 - 27053167
AN - SCOPUS:84962684984
SN - 1436-3291
VL - 20
SP - 246
EP - 253
JO - Gastric Cancer
JF - Gastric Cancer
IS - 2
ER -